Prospective trials of autologous transplantation in adults.
| . | Relapse* (%) . | Disease-Free Survival* (%) . | Overall Survival* (%) . | |||
|---|---|---|---|---|---|---|
| Trial . | Autograft . | Chemo . | Autograft . | Chemo . | Autograft . | Chemo . |
| Abbreviations: EORTC/GIMEMA, European Organization for Research and Treatment of Cancer/Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto; AML, acute myeloid leukemia; GOELAM, Groupe Ouest Est Leucemies Aigues Myeloblastiques; NA, not applicable; MRC, Medical Research Council. | ||||||
| * % at 4 years or beyond | ||||||
| EORTC/GIMEMA AML8 | 40 | 57 | 48 | 30 | 56 | 46 |
| GOELAM | NA | NA | 44 | 40 | 50 | 55 |
| MRC AML 10 | 37 | 58 P = 0.0007 | 53 | 40 P = 0.04 | 57 | 45 |
| . | Relapse* (%) . | Disease-Free Survival* (%) . | Overall Survival* (%) . | |||
|---|---|---|---|---|---|---|
| Trial . | Autograft . | Chemo . | Autograft . | Chemo . | Autograft . | Chemo . |
| Abbreviations: EORTC/GIMEMA, European Organization for Research and Treatment of Cancer/Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto; AML, acute myeloid leukemia; GOELAM, Groupe Ouest Est Leucemies Aigues Myeloblastiques; NA, not applicable; MRC, Medical Research Council. | ||||||
| * % at 4 years or beyond | ||||||
| EORTC/GIMEMA AML8 | 40 | 57 | 48 | 30 | 56 | 46 |
| GOELAM | NA | NA | 44 | 40 | 50 | 55 |
| MRC AML 10 | 37 | 58 P = 0.0007 | 53 | 40 P = 0.04 | 57 | 45 |